



Infectious Diseases Working Party

CHAIR: RAFAEL DE LA CAMARA
SECRETARY: DINA AVERBUCH
STATISTICIAN: GLORIA TRIDELLO
STUDY COORDINATOR: NINA KNELANGE
DATA MANAGER: LOTUS WENDEL

IDWP in 2020

MISSION

Mission of IDWP is to share the experience and develop cooperative studies to increase the knowledge in the field of diagnosis, prophylaxis and treatment of infectious complications in HSCT patients.

MAYOR ACHIEVEMENTS

IDWP Members continue their scientific and educational activity in the fields of bacterial, viral and fungal infections, including *Pneumocystis jirovecii*, parasitic infections, vaccinations, protective environment and guidelines development. In 2020, IDWP leaded and participated in several COVID19 initiatives: recommendations for SARS-CoV-2 management and vaccination, prospective study of SARS-CoV-2 in HSCT patients, participate in the EBMT COVID TASK force.

IDWP recent achievements were published in *Journal of Infectious Diseases*, *Bone Marrow Transplant*, and *Journal of Neurology*

PRINCIPLE RESEARCH STUDIES

COVID-19 STUDIES: 1) Impact of COVID-19 on stem cell transplant recipients and CAR-T cell recipients, 2) Impact of SARS-CoV-2 infection prior to stem cell transplantation

ONGOING OTHER PROJECTS INCLUDE:

RETROSPECTIVE: *Listeria* infections in hematopoietic stem cell transplant recipients

PROSPECTIVE NON-INTERVENTIONAL: 1) Impact of pre-existing invasive aspergillosis on allogeneic stem cell transplantation (IPAT), 2) Central nervous system complications following hematopoietic stem cell transplantation.

PROJECTS FOR WHICH FOLLOW-UP IS COLLECTED: Incidence and outcome of HHV-6 encephalitis in patients who undergo allogeneic haploidentical HSCT

KEY PUBLICATIONS 2020

SEASONAL HUMAN CORONAVIRUSES RESPIRATORY TRACT INFECTION IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Piñana et al, Journal of Infectious Diseases. doi: 10.1093/infdis/jiaa553

DEATH AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATIONS: CHANGES OVER CALENDAR YEAR TIME, INFECTIONS AND ASSOCIATED FACTORS. Styczynski et al, Bone Marrow Transplant. doi: 10.1038/s41409-019-0624-z

THE CHALLENGES OF COVID-19 AND HEMATOPOIETIC CELL TRANSPLANTATIONS; EBMT RECOMMENDATIONS FOR MANAGEMENT OF HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS, THEIR DONORS AND PATIENTS UNDERGOING CART T-CELL THERAPY. Ljungman et al, Bone Marrow Transplant. doi: 10.1038/s41409-020-0919-0

INTERCONTINENTAL STUDY ON PRE-ENGRAFTMENT AND POST-ENGRAFTMENT GRAM-NEGATIVE RODS BACTEREMIA IN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS: RISK FACTORS AND ASSOCIATION WITH MORTALITY. Averbuch et al, Journal of Infection. doi: 10.1016/j.jinf.2020.11.002

USE OF LETERMOVIR IN OFF-LABEL INDICATIONS: IDWP OF EBMT RETROSPECTIVE STUDY. Styczynski et al, Bone Marrow Transplant. doi: 10.1038/s41409-020-01166-w

CENTRAL NERVOUS SYSTEM DISORDERS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF THE INFECTIONS DISEASES WORKING PARTY OF EBMT. Schmidt-Hieber et al, J. Neurol. doi: 10.1007/s00415-019-09578-5

INCIDENCE AND OUTCOME OF KAPOSI SARCOMA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS AND A REVIEW OF THE LITERATURE, ON BEHALF OF IDWP OF EBMT. Cesaro et al, Bone Marrow Transplant. doi:10.1038/s41409-019-0644-8

CURRENT ANTIMICROBIAL PRACTICE IN FEBRILE NEUTROPENIA ACROSS EUROPE AND ASIA: THE EBMT IDWP SURVEY. Verlinden et al, Bone Marrow Transplant. doi: 10.1038/s41409-020-0811-y

EDUCATIONAL COURSES 2020

23RD IDWP EDUCATIONAL (FIRST ONLINE) (28 – 30 October 2020)

5TH INTERNATIONAL TRANSPLANT COURSE (4 – 6 November 2020)

Contact

For participation in, or information on IDWP studies, please contact the IDWP at the EBMT Leiden Study Unit, The Netherlands

[Rafael de la Camara](#)
IDWP Chair

[Nina Knelange](#)
IDWP Study coordinator

idwp.ebmt@lumc.nl

[Dina Averbuch](#)
IDWP Secretary

[Lotus Wendel](#)
IDWP Data manager

IDWP in 2021

STUDIES STARTING SOON:

COVID-19 STUDIES: 1) Pulmonary function before and after COVID-19, 2) Multisystem Inflammatory Syndrome in patients <21years, 3) Cycle threshold values, 4) Impact of SARS-CoV-2 pandemic in HSCT activity, 5) Prolonged shedding of SARS-CoV-2, 6) Pulmonary imaging, 7) Seroconversion in SARS-CoV-2 infection, 8) Cryopreservation of allogeneic HPC products, 9) Impact of COVID-19 vaccination in AA/PNH patients (collaboration SAAWP)

NON-COVID RETROSPECTIVE: 1) Atypical mycobacterial infections post-HSCT, 2) Study on the incidence and outcome of Adenovirus infection in patients who undergo haploidentical HSCT, 3) causes of death in patients with lymphoma and chronic leukemia, 4) survey on ICU admission and outcomes in patients who undergo HSCT, 5) Infectious complication in patients with autoimmune diseases undergoing auto-HSCT, 6) Infections after HCT in patients with preexisting diabetes mellitus, 7) Survey on risks associated with pet exposure in transplanted children

NON-COVID PROSPECTIVE: 1) Infections following CAR T-cell therapy, 2) Viral infections after unmanipulated allo-HSCT in pediatric patients.

IDWP AT 47TH ANNUAL MEETING OF EBMT (VIRTUAL):

IDWP SESSION

- Rafael de la Camara (*Spain*) - IDWP Update
- Dina Averbuch (*Israel*) - Current scientific proposals of IDWP
- Roy Chemaly (*United States*) – CMV T-cell immunity monitoring
- Dina Averbuch (*Israel*) – What is new in the field of Gram-negative infections in SCT patients?
- Jose Luis Piñana (*Spain*) – Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic hematopoietic stem cell transplantation
- Malgorzata Mikulska (*Italy*) – Hepatitis C and hepatitis E in SCT
- Martin Schmidt-Hieber (*Germany*) – Central nervous system (CNS) complications following HSCT

IDWP ORAL PRESENTATIONS

- Dina Averbuch (*Israel*) – Nocardiosis following hematopoietic cell transplantation: 20 years' experience
- Agnieszka Piekarska (*Poland*) – The management of *Clostridioides Difficile* Infections in patients after allogeneic hematopoietic cell transplantations

COVID-19 SESSIONS

- Patient, Family and Donor Day: COVID-19. (PFD3-1 – Panel discussion). Rafael de la Camara (*Spain*) **March 14 12:00-12:35**
- Role of SARS-CoV-2 testing for donors in the workup (CTD3-4 – Cell Therapy Day). Rafael de la Camara (*Spain*). **March 15 15:25-15:40**
- The IDWP-EBMT COVID 19 experience (Joint session JS2 ASTCT/CIBMTR/APMBMT). Rafael de la Camara (*Spain*) **March 15 17:06-17:24**
- EBMT recommendations and prospective registry study (SS6-1 – Covid 2). Per Ljungman (*Sweden*) **March 17 16:15-16:30**
- COVID-19: The EBMT recommendations for management of HCT patients and donors (NG13-3 – Nurses Education day). Per Ljungman (*Sweden*)
- COVID-19 vaccination in HSCT (JS5 – Joint session WBMT). Per Ljungman (*Sweden*)

OTHER INFECTIOUS RELATED SESSIONS

- Management of EBV-PTLD in 2021 (MTE-10, Meet the Expert). Jan Styczynski (*Poland*) **March 16 17:30-18:30 room MTE5**
- Patient infectious risk factors: What they are and how to deal with them (W06, Workshop). Simone Cesaro (*Italy*) **March 17 11:00-11:15**
- COVID-19 and other vaccines in HSCT recipients (MTE-12, Meet the Expert). Simone Cesaro (*Italy*) **March 17 12:30-13:30 room MTE2**
- Infectious complications (HDI6-2, How Do I). Jan Styczynski (*Poland*)
- Infectious complications (DM8-1, Data Management). Malgorzata Mikulska (*Italy*)
- Early infectious complications (E11-1, Educational). Jan Styczynski (*Poland*)
- New Treatment Paradigms CMV (IS16-8, Industry Symposium). Catherine Cordonnier (*France*) **March 14 15:30-15:42**
- Real World Evidence of CMV prophylaxis: a focus on CMV blips and treatment duration (IS19-3, Industry Symposium). Catherine Cordonnier (*France*) **March 14 16:55-17:15**

EDUCATIONAL ACTIVITIES IN 2021

EBMT infectious complication Summit: Focus on COVID-19

29 – 30 June, 1 July 2021 (*Information on the EBMT web*)

24th IDWP Educational Course - 24 – 26 November 2021

Annual online certificated course on Infections in HSCT recipients (with exam and CME credits) – to be launched in 2021